Anti-Retrovirals Flashcards
NRTI’s (5)
Zidovudine Lamivudine Abacavir Tenofovir disoproxil Emtricitabine
NNRTI’s (2)
Nevirapine
Efavirenz
Fusion Inhibitor
Enfuvirtide
Protease Inhibitors (3)
Ritonavir
Atazanavir
Darunavir
Co-Receptor Antagonist
Maraviroc
Integrase Inhibitors (3)
Raltegravir
Elvitegravir
Dolutegravir
Abacavir MOA
GUANOSINE ANALOGUE - incorporated into DNA and INHIBIT REVERSE TRANSCRIPTASE FUNCTION - leads to chain termination
activated by cellular kinases
Abacavir adverse reactions
ALLERGIC REACTION WITH HLA-B5707
Cardiac events
Lowers methadone effectiveness
Lamivudine MOA
Important characteristics (3)
CYTOSINE ANALOGUE - incorporated into DNA and INHIBIT REVERSE TRANSCRIPTASE FUNCTION - leads to chain termination
short half life
GI/CNS adverse effects with higher doses
single base change can cause high level resistance
Emtricitabine MOA
Important characteristics (2)
FLUORINATED ANALOGUE OF LAMIVUDINE - incorporated into DNA and INHIBIT REVERSE TRANSCRIPTASE FUNCTION - leads to chain termination
Longer half life than lamivudine
Single mutation can cause resistance
Tenofovir MOA
Given as?
ADENOSINE ANALOGUE - incorporated into DNA and INHIBIT REVERSE TRANSCRIPTASE FUNCTION - leads to chain termination
tenofovir disoproxil - better absorption
Tenofovir adverse effects
GI headache asthenia Renal and bone toxicity CROSSES PLACENTA
Zidovudine MOA
Two significant adverse effects
DEOXYTHYMIDINE ANALOGUE - incorporated into DNA and INHIBIT REVERSE TRANSCRIPTASE FUNCTION - leads to chain termination
Myelosuppression
Nail hyperpigmentation
Non-nucleoside reverse transcriptase inhibitors MOA
BIND AND INHIBIT REVERSE TRANSCRIPTASE ENZYME
DO NOT REQUIRE ACTIVATION/PHOSPHORYLATION
Bind site separate from active site
NOT ACTIVE AGAINST HIV 2
Common adverse effects of NNRTI’s
rash, steven johnson syndrome, hepatotoxicity
DRUG-DRUG INTERACTIONS WITH P450 ENZYMES
Efavirenz Important characteristics
TERATOGENIC (in primate models)
Cross resistance with nevirapine
Contraindicated in pregnancy
Nevirapine Important Characteristics
Lipophilic - high oral bioavailability
PREVENTION OF VERTICAL TRANSMISSION - CAN BE USED IN PREGNANCY
Protease Inhibitors MOA
MIMIC PEPTIDE TARGETS OF PROTEASES
block maturation of virion particles after budding
Protease Inhibitors common adverse effects
hyperlipidemia, lipodystrophy, hepatotoxic, GI interolance, increased bleeding risk
DRUG-DRUG INTERACTIONS with P450 activity
Atazanavir Important characteristics
REQUIRES ACID FOR ABSORPTION - don’t use with PPI’s
Peripheral neuropathy, hyperbilirubinemia potentially
Ritonavir Important Characteristics
peptidomimetic PI
POTENT INHIBITOR OF P450 ENZYME
USED IN LOW DOSES AS A BOOSTER - INCREASES HALF LIFE OF CO-ADMINISTERED ARV’s
Darunavir Important Characteristics
CO-ADMIN WITH P450 INHIBITOR
increase liver enzymes and serum amylase
90% of HIV-1 with resistance to others are STILL SUSCEPTIBLE TO DARUNAVIR
Co-receptor Antagonist MOA
BINDS CCR5 CO-RECEPTOR TO PREVENT VIRAL ATTACHMENT TO HOST CELLS
Maraviroc important characteristics
Allergic reaction, cardiac events in susceptible patients
resistance through CHANGE IN TROPISM (CCR5 predominant to CXCR4) or MUTATIONS IN gp120
Fusion inhibitor MOA
prevents fusion of viral membrane with host cell membrane
PREVENTS CONFORMATIONAL CHANGE OF GP120 THAT WOULD NORMALLY BRING MEMBRANES TOGETHER
Enfuvirtide important characteristics
PAINFUL ERYTHEMATOUS NODULE AT INJECTION SITE
ONLY PARENTERALLY DELIVERED ARV
RESERVED FOR TREATMENT EXPERIENCED PATIENTS WITH INCREASING VIRAL LOAD in the face of consistent ARV treatment
Integrase Inhibitor MOA
PREVENTS VIRAL GENETIC MATERIAL FROM BEING INCORPORATED INTO HOST CELL GENOME
Raltegravir important characteristics
MYOPATHY, RHABDOMYOLYSIS
single mutation can confer resistance
Elvitegravir important characteristics
REQUIRES CO ADMIN WITH “BOOSTERS” (cobicistat or ritonavir)
Dolutegravir Important Characteristics
Hypersensitivity reactions, elevation of aminotransferases, fat redistribution syndrome
RETAINS ACTIVITY AGAINST SOME VIRUSES THAT ARE RESISTANT TO BOTH RALTEGRAVIR AND ELVITEGRAVIR